

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/009,473	
			Filing Date	November 8, 2001	
			First Named Inventor	Hagen, Michael	
			Group Art Unit	1648	
Examiner Name	Emily M. Le				
Attorney Docket Number	ACY33482				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If known)			
	1.	6,071,893		Graham et al.	06/06/2000	
	2.	6,514,503	B1	Gizurason et al.	02-04-2003	
	3.	6,929,794	B1	Mills et al.	08-16-2005	
	4.	5,723,130		Hancock et al.	03-03-1998	
	5.	5,679,356		Bonnem et al.	10-21-1997	
	6.	5,976,539		Scott et al.	11-02-1999	
	7.	5,723,127		Scott et al.	03-03-1998	
	8.	5,980,911		Corner et al.	11-09-1999	
	9.	6,024,965		van Baalen et al.	02-15-2000	
	10.	6,113,918		Johnson et al.	09-05-2000	
	11.	6,096,313		Jager et al.	08-01-2000	
	12.	6,613,337	B1	Reed et al.	09-02-2003	
	13.	6,488,936	B1	Mishkin et al.	12-03-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If known)				
	14.	WO	96/10423		Noguchi et al.	04-11-1996		<input type="checkbox"/>
	15.	WO	96/11019		Graham et al.	04-18-1996		<input type="checkbox"/>
	16.	WO	98/50399		Johnson et al.	11-12-1998		<input type="checkbox"/>
	17.	WO	00/60084		Vinals Y De Bassols et al.	10-12-2000		<input type="checkbox"/>
	18.	WO	00/69456		Hagen	11-23-2000		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published		T
	19.	USPTO FINAL OFFICE ACTION, MAILED MARCH 17, 2008		<input type="checkbox"/>
		In re of Application of:	HAGEN, Michael	
		Application No.:	10/416,262	
		Filed:	May 8, 2003	
		For:	ADJUVANT COMBINATION FORMULATIONS	
		Confirmation No.:	1455	
		Customer Number:	25291	
		Docket No.:	AM100449	
	20.	USPTO FINAL OFFICE ACTION, MAILED OCTOBER 17, 2008		<input type="checkbox"/>
		In re of Application of:	HAGEN, Michael	
		Application No.:	11/544,056	
		Filed:	October 6, 2006	
		For:	ADJUVANT COMBINATION FORMULATIONS	
		Confirmation No.:	7860	
		Customer Number:	25291	
		Docket No.:	AM100449 D1	

Examiner Signature	/Emily Le/	Date Considered	06/24/2009
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPE 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/009,473	
			Filing Date	November 8, 2001	
			First Named Inventor	Hagen, Michael	
			Group Art Unit	1648	
Examiner Name	Emily M. Le				
Attorney Docket Number	ACY33482				
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Initials*	Cite No		T
	21.	Silla, S. et al., "Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL," 1999, European Cytokine Network, Vol. 10(2), pages 181-189	<input type="checkbox"/>
	22.	Hancock, G. E. et al., "QS-21 Synergizes with Recombinant Interleukin-12 to Create a Potent Adjuvant Formulation for the Fusion Protein of Respiratory Syncytial Virus," 2000, Viral Immunology, Vol. 13(4), pages 503-509	<input type="checkbox"/>
	23.	Weinberg, A. et al., "Recombinant Interleukin 2 As An Adjuvant for Vaccine-induced Protection," 1988 Jan 1, Journal of Immunology, Vol. 140(1), pages 294-299	<input type="checkbox"/>
	24.	Datta, S. K. et al, "Antigen-immunostimulatory oligo-nucleotide conjugates: mechanisms and applications," 2004 June, Immunological Reviews, Vol. 199, pages 217-226, Abstract Only	<input type="checkbox"/>
	25.	Schoenhaut, D. S. et al., "Cloning and Expression of Murine IL-12," 1992 Jun 1, Journal of Immunology, Vol. 148(11), pages 3433-3440	<input type="checkbox"/>
	26.	Singh, M. et al., "Advances in vaccine adjuvants," 1999 Nov, Nature Biotechnology, Vol. 17(11), pages 1075-1081	<input type="checkbox"/>
	27.	Vaslin, B. et al., "Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection?" 1994, Vaccine, Vol. 12, pages 1132-1140	<input type="checkbox"/>

Examiner Signature	/Emily Le/	Date Considered	06/24/2009
--------------------	------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.